Pure Global AI
NCT06333028Not yet recruiting

A Study to Evaluate the enVista® Aspire (EA) Intraocular Lens in Subjects Undergoing Cataract Extraction

A Non-interventional, Prospective, Multicenter, Single Arm, Post-Marketing Clinical Study to Evaluate the enVista® Aspire (EA) Intraocular Lens in Subjects Undergoing Cataract Extraction.
Bausch & Lomb IncorporatedClinicalTrials.govdeviceDevice trial
Study focus
Disease/Condition
Cataract
Drug/Device/Intervention
enVista Aspire EA IOLs
Study type
Observational
Intervention type
device
Sponsor & location
Primary sponsor
Bausch & Lomb Incorporated
Location
Dover,Woodland Park,Garden City,Charleston,Sugar Land,Mount Pleasant, United States of America
Timeline & enrollment
Phase
N/A
Start date
Jun 01, 2024
End date
Sep 01, 2024
Enrollment
100 participants
Primary outcome

Mean binocular BCDVA (logMAR) at Visit 1

Summary

A Study to Evaluate the enVista® Aspire (EA) intraocular lens in Subjects Undergoing Cataract
 Extraction

ICD-10 classifications
Other cataractCataract, unspecifiedComplicated cataractOther specified cataractSenile cataract
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06333028
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06333028 through Pure Global AI's free database. This phase not specified trial is sponsored by Bausch & Lomb Incorporated and is currently Not yet recruiting. The study focuses on Cataract. Target enrollment is 100 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.